You are here

Investigational New Drug Application Filed for Phenoptin, Treatment for Phenylketonuria

NOVATO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for Phenoptin™, BioMarin's proprietary oral formulation of 6R-BH4, for the treatment of phenylketonuria (PKU). The company expects to initiate a clinical study of Phenoptin based on this IND by the end of 2004.

"Our recently submitted IND contains an unusually large set of data on 6R- BH4 that we expect will advance this program toward a later stage of development and will enable us to initiate a clinical study later this year," stated Emil Kakkis, M.D., Ph.D., Senior Vice President of Business Operations at BioMarin. "We look forward to having discussions with the FDA in the coming months that will help define the specific timeline and development course for this much needed therapeutic option for people living with PKU."

On July 20, 2004, BioMarin announced positive results from an investigator-sponsored pilot clinical study of oral 6R-BH4 in PKU patients. Consistent with previous studies of 6R-BH4, approximately half of the patients in the study experienced a substantial reduction in blood phenylalanine levels without serious adverse effects, suggesting that Phenoptin could be a valuable therapeutic for managing PKU.

Louis Drapeau, acting Chief Executive Officer of BioMarin stated, "The passion and tenacity the BioMarin team has for developing new therapeutics for serious diseases has contributed greatly to the rapid development of our PKU program." Mr. Drapeau continued, "In addition to these important developments in our PKU program, we also remain on track to file for marketing authorization for Aryplase™, potentially our third approved product, in both the United States and European Union in the fourth quarter of this year. BioMarin is moving aggressively ahead with its programs in all areas."

Source: BioMarin Pharmaceutical Inc.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy